HUMANIGEN INC (HGEN)       0.1427  +0 (+0.49%)

0.1427  +0 (+0.49%)

US4448632038 - Common Stock

HUMANIGEN INC0.1427

NASDAQ:HGEN (12/1/2022, 10:48:23 AM)+0 (+0.49%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 02-27 2023-02-27/dmh
Ins Owners 0.02% Inst Owners 6.11%
Market Cap 16.99M Shares 119.08M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 46.67
IPO 01-30 2013-01-30

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HGEN Daily chart

Company Profile

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily with acute and chronic conditions. The Company’s lead product candidate, lenzilumab, and its other two product candidates, ifabotuzumab (iFab) and HGEN005, are Humaneered monoclonal antibodies. Its lenzilumab product is a monoclonal antibody that has been demonstrated to neutralize human granulocyte-macrophage colony-stimulating factor (GM-CSF). Its ifabotuzumab product is focused on the EphA3 receptor. Its HGEN005 product is selectively targeting the eosinophil receptor EMR1. Its subsidiaries include Humanigen, Ltd., Humanigen Australia Pty, Ltd. and Humanigen Europe, Ltd.

Company Info

HUMANIGEN INC

830 Morris Turnpike, 4Th Floor

Short Hills NEW JERSEY 94010

P: 19732003100.0

CEO: Cameron Durrant

Employees: 11

Website: https://www.humanigen.com/

HGEN News

News Image6 days ago - ChartmillWhat's going on in today's after hours session

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

News Image8 days ago - ChartmillWhat's going on in today's after hours session

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

News Image17 days ago - NewsfileHumanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused...

News Image21 days ago - NewsfileHumanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused...

News Imagea month ago - NewsfileHumanigen Announces Retention of SC&H Capital as Financial Advisor

Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused...

News Imagea month ago - SBWireNASDAQ:HGEN Investor Alert: Deadline on October 25, 2022 in Lawsuit Against Humanigen, Inc.

San Diego, CA -- (SBWIRE) -- 10/26/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 25, 2022 in the lawsuit filed for certain investors of Humanigen, Inc. (NASDAQ:HGEN).

HGEN Twits

Here you can normally see the latest stock twits on HGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example